Predicting risk of cancer during HIV infection: The role of inflammatory and coagulation biomarkers

AIDS

Volumn 27, Issue 9, 2013, Pages 1433-1441

  Borges, Álvaro H ^a   Silverberg, Michael J ^b   Wentworth, Deborah ^c   Grulich, Andrew E ^d   Fätkenheuer, Gerd ^e   Mitsuyasu, Ronald ^f   Tambussi, Giuseppe ^g   Sabin, Caroline A ^h   Neaton, James D ^c   Lundgren, Jens D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DIVISION OF RESEARCH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; C reactive protein; Cancer; D dimer; HIV; Interleukin 6

Indexed keywords

C REACTIVE PROTEIN; D DIMER; INTERLEUKIN 6;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879125950     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835f6b0c     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
2. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67.
3. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736.
4. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52:203-208.
5. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23:2337-2345.
6. Grulich AE, Jin F, Poynten IM, Vajdic CM. HIV, cancer, and aging. Sex Health 2011; 8:521-525.
7. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
8. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20:2551-2559.
9. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52: 1458-1465.
10. Worm S, Bower M, Reiss P, Grulich A, Fontas E, Bonnet F, et al. Non-AIDS defining malignancies (NADM) and immuno-suppression: the D:A:D study. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, Washington (Washington 2012).
11. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103:753-762.
12. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
13. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963.
14. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
15. Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, et al. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011; 121:2436-2446.
16. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366:610-618.
17. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-636.
18. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14:2413-2418.
19. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24:5216-5222.
20. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011; 103:1112-1122.
21. Breen EC, van der Meijden M, Cumberland W, Kishimoto T, Detels R, Martínez-Maza O. The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999; 92:293-2999.
22. Breen EC, Hussain SK, Magpantay L, Jacobson LP, Detels R, Rabkin CS, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011; 20:1303-1314.
23. Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-1559.
24. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
25. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009; 10:321-322.
26. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. J Am Stat Assoc 1989; 84:1065-1073.
27. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70 (Suppl 1):104-108.
28. Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, et al. Relation betweencommon polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 2006; 12:5037-5043.
29. Nogueira de Souza NC, Brenna SM, Campos F, Syrjänen KJ, Baracat EC, Silva ID. Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 2006; 16:1278-1282.
30. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, et al. Strong association of interleukin-6-174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 2006; 21:246-250.
31. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27:2217-2224.
32. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010; 28:2719-2726.
33. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19:1427-1432.
34. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15:1331-1335.
35. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008; 26:4834-4842.